Activity of newer fluoroquinolones in vitro against gram-positive bacteria.
Several newer fluoroquinolones, which have been recently introduced or are under investigation, display substantially greater potency against gram-positive organisms than the older generation agents of this class. Nevertheless, for problem organisms including methicillin-resistant strains of Staphylococcus aureus and many Enterococcus faecium, concentrations of newer antimicrobials required to inhibit 90% of organisms in the collections studied remain above those that are projected to be achievable with clinical use. Nevertheless, enhanced potency of several newer quinolones may result in a favourable pharmacodynamic profile leading to improved outcomes against gram-positive infections and possibly to the delayed or diminished emergence of resistance to these agents.
Eliopoulos
G M
GM
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA. geliopou@caregroup.harvard.edu
D000890:Anti-Infective Agents / Q000494:pharmacology*; D016983:Enterococcus / Q000187:drug effects; D024841:Fluoroquinolones; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones